AU8144098A - Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria - Google Patents

Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria Download PDF

Info

Publication number
AU8144098A
AU8144098A AU81440/98A AU8144098A AU8144098A AU 8144098 A AU8144098 A AU 8144098A AU 81440/98 A AU81440/98 A AU 81440/98A AU 8144098 A AU8144098 A AU 8144098A AU 8144098 A AU8144098 A AU 8144098A
Authority
AU
Australia
Prior art keywords
seq
antibody
gram positive
arg
positive bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU81440/98A
Other languages
English (en)
Inventor
Gerald W. Fischer
Richard F. Schuman
Jeffrey L. Stinson
Hing Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunol Molecular Corp
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Found For Advancement Of Military Medicine
Sunol Molecular Corp
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Found For Advancement Of Military Medicine, Sunol Molecular Corp, Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Found For Advancement Of Military Medicine
Publication of AU8144098A publication Critical patent/AU8144098A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU81440/98A 1997-06-16 1998-06-16 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria Abandoned AU8144098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4987197P 1997-06-16 1997-06-16
US60049871 1997-06-16
PCT/US1998/012402 WO1998057994A2 (en) 1997-06-16 1998-06-16 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2002300698A Division AU2002300698A1 (en) 1997-06-16 2002-08-21 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

Publications (1)

Publication Number Publication Date
AU8144098A true AU8144098A (en) 1999-01-04

Family

ID=21962176

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81440/98A Abandoned AU8144098A (en) 1997-06-16 1998-06-16 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

Country Status (10)

Country Link
US (5) US6610293B1 (https=)
EP (2) EP0986577B1 (https=)
JP (2) JP4691225B2 (https=)
AT (1) ATE497977T1 (https=)
AU (1) AU8144098A (https=)
CA (1) CA2293732A1 (https=)
DE (1) DE69842129D1 (https=)
DK (1) DK0986577T3 (https=)
ES (1) ES2363689T3 (https=)
WO (1) WO1998057994A2 (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
DE19912706A1 (de) * 1999-03-05 2000-09-07 Petry Genmedics Gmbh Dr Wirkstoffe zur Bekämpfung von bakteriellen Infektionserkrankungen
US6790661B1 (en) * 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
WO2002045742A2 (en) * 2000-09-12 2002-06-13 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
AU2012254925B2 (en) * 2001-12-21 2016-10-13 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
AU2002364740A1 (en) * 2001-12-21 2003-07-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20030224000A1 (en) * 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
EP1567868A4 (en) * 2002-12-02 2008-02-06 Biosynexus Inc CELL WALL TEICHONSURE AS A GOAL F RANTI-STAPHYLOCOCCUS THERAPIES AND VACCINATES
AU2004255553B2 (en) * 2003-06-19 2009-08-20 Genentech, Inc. Compositions and methods for treating coagulation related disorders
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
GB2408573A (en) * 2003-11-25 2005-06-01 Univ Leicester Assay for the interaction of L-Ficolin with lipoteichoic acid
KR20070058631A (ko) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US20060188526A1 (en) * 2005-02-24 2006-08-24 Cunnion Kenji M Method for enhancing the immune response to Staphylococcus aureus infection
WO2007008904A2 (en) 2005-07-08 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
EA021767B1 (ru) * 2006-06-06 2015-08-31 Круселл Холланд Б.В. Антитела человека с киллерной активностью в отношении энтерококков и стафилококков и их применение
AU2012268821B2 (en) * 2006-06-06 2016-06-02 Janssen Vaccines & Prevention B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
WO2007141274A2 (en) 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
PT2121920E (pt) 2007-03-01 2011-10-03 Symphogen As Método de clonagem de anticorpos cognatos
BRPI0811193A2 (pt) 2007-05-31 2014-11-11 Merck & Co Inc Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
EP2185190B1 (en) * 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US20100260752A1 (en) * 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
SI2454284T1 (en) 2009-07-15 2018-07-31 Aimm Therapeutics B.V. Compounds that specifically bind to Gram-positive bacteria
EA025367B1 (ru) 2009-08-17 2016-12-30 Тракон Фармасьютикалз, Инк. Комбинированная терапия рака с помощью антител против эндоглина и агентов против vegf
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US20110236399A1 (en) * 2010-03-29 2011-09-29 Biosynexus Incorporated Compositions and methods for prophylactic and therapeutic treatment of infection
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR112014003315A2 (pt) 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
WO2013112916A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
AU2013252883B2 (en) 2012-04-26 2018-05-17 University Of Chicago Staphylococcal coagulase antigens and methods of their use
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
EP2872535A1 (en) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2015100448A2 (en) 2013-12-28 2015-07-02 Longhorn Vaccines And Diagnostics, Llc Multimodal antimicrobial therapy
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
WO2017137954A2 (en) 2016-02-12 2017-08-17 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원
EP4430058A2 (en) * 2021-11-12 2024-09-18 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and vaccines in the treatment and prevention of infections
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1499035A (en) 1975-04-10 1978-01-25 Ts Nii Gematologii I Perelivan Antistaphylococcus human immune globulin and method of preparing same
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4732757A (en) 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
US4235869A (en) * 1978-05-16 1980-11-25 Syva Company Assay employing a labeled Fab-fragment ligand complex
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
FR2475900A1 (fr) 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4744982A (en) * 1982-08-24 1988-05-17 Hunter Kenneth W Human monoclonal antibody reactive with polyribosylribitol phosphate
US4954449A (en) * 1982-08-24 1990-09-04 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibody reactive with polyribosylribitol phosphate
US4482483A (en) 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4719290A (en) 1983-09-02 1988-01-12 Armour Pharmaceutical Corporation Composition of intravenous immune globulin
US4596769A (en) * 1984-03-05 1986-06-24 Temple University Monoclonal antibodies to peptidoglycan and methods of preparing same
US5043267A (en) * 1984-05-18 1991-08-27 E. I. Du Pont De Nemours And Company Method for rapid detection of bacterial and fungal infection
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4888279A (en) * 1984-12-21 1989-12-19 Thomas Jefferson University Novel immunosorbent assays employing antibiotic keying agents
DE3516119A1 (de) * 1985-05-04 1986-11-06 Biotest Pharma GmbH, 6000 Frankfurt Polyvalentes hyperimmunglobulin-praeparat
FR2581877B1 (fr) 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US5034515A (en) 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
JP2666212B2 (ja) * 1988-03-07 1997-10-22 鐘紡株式会社 抗体およびそれを有効成分とする齲蝕予防剤の製造方法
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5069896A (en) * 1989-06-01 1991-12-03 The Gillette Company Malodor inhibiting skin deodorant composition comprising a monoclonal antibody and method of deodorizing
US5440014A (en) 1990-08-10 1995-08-08 H+E,Uml/Oo/ K; Magnus Fibronectin binding peptide
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
USRE37525E1 (en) * 1991-05-01 2002-01-22 Henry M. Jackson Foundation Method for treating infectious respiratory diseases
AU665025B2 (en) * 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69233012T2 (de) 1991-11-22 2003-11-06 Fattom, Ali Ibrahim Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
EP0628056A4 (en) 1992-02-25 1997-03-05 Jackson H M Found Military Med TARGETED HUMAN IMMUNGLOBULINE TO PREVENT AND TREAT STAPHYLOCOCCEN INFECTIONS.
DK0635132T4 (da) 1992-03-19 2008-08-25 Jackson H M Found Military Med Bredt reaktive opsoniske antistoffer, som reagerer med fælles stafylokok-antigener
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5545721A (en) 1992-12-21 1996-08-13 Ophidian Pharmaceuticals, Inc. Conjugates for the prevention and treatment of sepsis
WO1994015640A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5955078A (en) 1993-02-05 1999-09-21 Smithkline Beecham P.L.C. Fibronectin binding protein polypeptides
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US5354654A (en) 1993-07-16 1994-10-11 The United States Of America As Represented By The Secretary Of The Navy Lyophilized ligand-receptor complexes for assays and sensors
US5624904A (en) 1993-11-17 1997-04-29 Massachusetts Institute Of Technology Method for treating gram positive septicemia
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
EP0792162B1 (en) * 1994-09-16 2005-11-09 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
WO1996009321A1 (en) 1994-09-21 1996-03-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
FR2729960A1 (fr) * 1995-01-30 1996-08-02 Bio Merieux Polypeptides mimotopes de toxoplasma gondii et applications
CN1113102C (zh) * 1995-01-30 2003-07-02 彼得·特鲁格 抗肿瘤制剂
WO1996039518A1 (en) * 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6288214B1 (en) * 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
GB9614274D0 (en) * 1996-07-06 1996-09-04 Univ Manchester Treatment and diagnosis of infections of gram positive cocci
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6294177B1 (en) * 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US6487198B1 (en) 1998-06-16 2002-11-26 Mci Communications Corporation Method and system for unloading T1 payloads from ATM cells
AU6033299A (en) * 1998-09-14 2000-04-03 Nabi Compositions of beta-glucans and specific igiv
US6365156B1 (en) * 1999-04-16 2002-04-02 Osel, Inc. Method for improving the half-life of soluble viral-specific ligands on mucosal membranes
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria

Also Published As

Publication number Publication date
DK0986577T3 (da) 2011-05-23
ATE497977T1 (de) 2011-02-15
US6939543B2 (en) 2005-09-06
WO1998057994A2 (en) 1998-12-23
JP4691225B2 (ja) 2011-06-01
US20060002939A1 (en) 2006-01-05
WO1998057994A3 (en) 1999-03-25
US7511122B2 (en) 2009-03-31
EP2357198A1 (en) 2011-08-17
US8372958B2 (en) 2013-02-12
US20100221822A1 (en) 2010-09-02
JP2011026327A (ja) 2011-02-10
ES2363689T3 (es) 2011-08-11
US6610293B1 (en) 2003-08-26
JP2002503966A (ja) 2002-02-05
EP0986577A2 (en) 2000-03-22
US20040013673A1 (en) 2004-01-22
DE69842129D1 (de) 2011-03-24
CA2293732A1 (en) 1998-12-23
US7884198B2 (en) 2011-02-08
US20020082395A1 (en) 2002-06-27
EP0986577B1 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
EP0986577B1 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
AU2009202762B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
CA2525657C (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats o6 of pseudomonas aeruginosa
JP2005514053A6 (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
WO1992016624A1 (en) Monoclonal antibody against lps core
EP1690875A1 (en) Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
AU2010201603B2 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
Borghesi et al. Increase of cross (auto)-reactive antibodies after immunization in aged mice: a cellular and molecular study
AU2012201369A1 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
HK1160872A (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
AU2012254925B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: THE NAME OF THE APPLICANT IN REGARD TO PATENT APPLICATION NUMBER 81440/98 SHOULD INCLUDE: SUNOL MOLECULAR CORPORATION

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted